CHATTEM, INC D/B/A OPELLA

Lobbying for CHATTEM, INC D/B/A OPELLA · Healthcare related to nonprescription drugs and dietary supplements.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · New Jersey · House · $230,000.00 expenses · posted Apr 17, 2025

Lobbying activity 1

Health Issues

Non-prescription drug issues. Monograph reauthorization. Rx to OTC switch. HSA/FSA.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.